<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pbd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pbd</book-part-id>
      <title-group>
        <title>Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Steinberg</surname>
            <given-names>Steven J</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>The Peroxisomal Diseases Laboratory<break/>Kennedy Krieger Institute<break/>Neurology, Johns Hopkins University School of Medicine<break/>Baltimore, Maryland</aff>
          <email>steinbergs@kennedykrieger.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raymond</surname>
            <given-names>Gerald V</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Neurogenetics <break/>Kennedy Krieger Institute <break/>Neurology, Johns Hopkins University School of Medicine<break/>Baltimore, Maryland</aff>
          <email>raymond@kennedykrieger.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Braverman</surname>
            <given-names>Nancy E</given-names>
          </name>
          <degrees>MS, MD</degrees>
          <aff>Departments of Human Genetics McGill University - Montreal Children's Hospital Research Institute<break/>Montreal, Quebec, Canada</aff>
          <email>nancy.braverman@mcgill.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moser</surname>
            <given-names>Ann B</given-names>
          </name>
          <degrees>BA</degrees>
          <aff>The Peroxisomal Diseases Laboratory <break/>Kennedy Krieger Institute <break/>Neurology, Johns Hopkins University School of Medicine<break/>Baltimore, Maryland</aff>
          <email>mosera@kennedykrieger.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>12</day>
          <month>12</month>
          <year>2003</year>
        </date>
        <date date-type="updated">
          <day>18</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="revised">
          <day>10</day>
          <month>5</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="dmn" document-type="chapter">Permanent Neonatal Diabetes Mellitus</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="perrault" document-type="chapter">Perrault Syndrome</related-object>
      <abstract id="pbd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Peroxisome biogenesis disorders, Zellweger syndrome spectrum (PBD, ZSS) is a continuum comprising three phenotypes &#x02014; Zellweger syndrome (ZS), the most severe; neonatal adrenoleukodystrophy (NALD); and infantile Refsum disease (IRD), the least severe &#x02014; that were originally described before the biochemical and molecular bases of these disorders had been fully determined. Individuals with PBD, ZSS usually come to clinical attention in the newborn period or later in childhood. In the newborn period, affected children are hypotonic, feed poorly, and have distinctive facies, seizures, and liver cysts with hepatic dysfunction. Bony stippling (chondrodysplasia punctata) of the patella(e) and other long bones may occur. Infants with ZS are significantly impaired and typically die during the first year of life, usually having made no developmental progress. Older children have retinal dystrophy, sensorineural hearing loss, developmental delay with hypotonia, and liver dysfunction. The clinical courses of NALD and IRD are variable and may include developmental delays, hearing loss, vision impairment, liver dysfunction, episodes of hemorrhage, and intracranial bleeding. While some children can be very hypotonic, others learn to walk and talk. The condition is often slowly progressive.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PBD, ZSS can be definitively determined by biochemical assays. Biochemical abnormalities detected in blood and/or urine should be confirmed in cultured fibroblasts. Measurement of plasma very-long-chain fatty acid (VLCFA) levels is the most commonly used and most informative initial screen. Elevation of C26:0 and C26:1 and the ratios C24/C22 and C26/C22 is consistent with a defect in peroxisomal fatty acid metabolism. Pathogenic variants in twelve different <italic toggle="yes">PEX</italic> genes (<italic toggle="yes">PEX1</italic>, <italic toggle="yes">PXMP3</italic> [<italic toggle="yes">PEX2</italic>], <italic toggle="yes">PEX3</italic>, <italic toggle="yes">PEX5</italic>, <italic toggle="yes">PEX6</italic>, <italic toggle="yes">PEX10</italic>, <italic toggle="yes">PEX12</italic>, <italic toggle="yes">PEX13</italic>, <italic toggle="yes">PEX14</italic>, <italic toggle="yes">PEX16</italic>, <italic toggle="yes">PEX19</italic>, and <italic toggle="yes">PEX26</italic>) &#x02014; those that encode peroxins, the proteins required for normal peroxisome assembly &#x02014; have been identified in PBD, ZSS. Pathogenic variants in <italic toggle="yes">PEX1</italic>, the most common cause of PBD, ZSS, are observed in about 68% of affected individuals.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> The focus is on symptomatic therapy, and may include: gastrostomy to provide adequate calories, hearing aids, cataract removal in infancy, glasses, vitamin supplementation, primary bile acid therapy, antiepileptic drugs, and possibly monitoring for hyperoxaluria.</p>
          <p><italic toggle="yes">Surveillance</italic>: Annual hearing and ophthalmologic evaluations, monitoring of coagulation factors, and tests of liver function.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Cow's milk products to reduce exposure to phytanic acid.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>The Zellweger syndrome spectrum of the peroxisome biogenesis disorders is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic alleles of an affected family member have been identified. Prenatal diagnosis by biochemical testing is also possible; however, the biochemical defects in cultured fibroblasts from an affected family member must be confirmed first, since the biochemical defects present in body fluids or liver may not be detectable in cultured cells (a phenomenon called "peroxisomal mosaicism").</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pbd.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="pbd.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_pbd.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_pbd.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Zellweger syndrome</p></list-item><list-item><p>Neonatal adrenoleukodystrophy</p></list-item><list-item><p>Infantile Refsum disease</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="pbd.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="pbd.Diagnosis">
        <title>Diagnosis</title>
        <sec id="pbd.Testing">
          <title>Testing</title>
          <p><bold>Biochemical testing.</bold> Biochemical assays can determine definitively whether an individual has a peroxisomal biogenesis disorder, Zellweger syndrome spectrum (PBD, ZSS).</p>
          <p>The battery of biochemical analyses used to diagnose PBD is summarized in <xref ref-type="table" rid="pbd.T.specialized_biochemical_testing_in">Table 1</xref>.</p>
          <p>The measurement of plasma very-long-chain fatty acid (VLCFA) concentrations is the most commonly used and most informative initial screen. Elevation of the plasma concentrations of C26:0 and C26:1 and the ratios of C24/C22 and C26/C22 is consistent with a defect in peroxisomal fatty acid metabolism. The degree of VLCFA plasma concentration elevation may vary, with a small percentage of individuals demonstrating only modest elevations.</p>
          <p>An elevation of only one or two of these parameters warrants further evaluation and may require repeat analysis of a fasting specimen or measurement of other analytes listed in <xref ref-type="table" rid="pbd.T.specialized_biochemical_testing_in">Table 1</xref>.</p>
          <table-wrap id="pbd.T.specialized_biochemical_testing_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Specialized Biochemical Testing in PBD, ZSS</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Compound</th>
                  <th id="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test</th>
                  <th id="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Expected Findings</th>
                  <th id="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Limitations of Test</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Very-long-chain fatty acids (VLCFA)</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Plasma concentration</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Elevated plasma concentrations of C26:0 and C26:1; elevated ratios of C24/C22 and C26/C22&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-fasting samples, hemolyzed samples, or an individual on a ketogenic diet can cause false-positive results. Normal in RCDP.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Phytanic acid and pristanic acid&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Plasma concentration</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Increased concentrations of phytanic acid and/or pristanic acid</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Branched-chain fatty acid accumulation occurs only through dietary intake of phytanic acid. Thus, phytanic and pristanic acid levels are normal in a neonate with a PBD.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Plasmalogens</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Erythrocyte membrane concentrations</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Profoundly diminished concentration of C16 and C18 plasmalogens (possible)</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Concentration of erythrocyte plasmalogens may improve with age. Not all newborns with PBD have reduced levels.</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Pipecolic acid</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Plasma/urine concentration</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Increased concentration of pipecolic acid in both plasma and urine</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Urinary excretion of pipecolic acid is high in the neonatal period and diminishes with age.&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Bile acids</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Plasma/urine concentration</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Accumulation of intermediates THCA and DHCA</td>
                  <td headers="hd_h_pbd.T.specialized_biochemical_testing_in_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Some defects may be subtle.</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>RCDP = <related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter">rhizomelic chondrodysplasia punctata</related-object></p>
              </fn>
              <fn>
                <p>DHCA = dihydroxycholestanoic acid</p>
              </fn>
              <fn>
                <p>THCA = trihydroxycholestanoic acid</p>
              </fn>
              <fn id="pbd.TF.1.1">
                <label>1. </label>
                <p>Low plasma concentration of LDL and HDL can cause false-negative results. In a person with low plasma concentrations of LDL and HDL without a defect in peroxisomal fatty acid metabolism, the plasma concentration of specific fatty acids (C22:0, C24:0, C26:0, etc) are significantly lower than normal control levels. Individuals with defects in peroxisomal fatty acid metabolism and very low LDL and HDL concentrations do not have significant elevations in C26:0 and C26:1, but do have modest elevations in the ratios of C24/C22 and C26/C22.</p>
              </fn>
              <fn id="pbd.TF.1.2">
                <label>2. </label>
                <p>This analysis is usually included in VLCFA measurement.</p>
              </fn>
              <fn id="pbd.TF.1.3">
                <label>3. </label>
                <p>Pipecolic acid measurement is an adjunct to more definitive biomarkers such as plasma VLCFA and erythrocyte plasmalogen levels. Elevations in pipecolic acid can occur in <related-object link-type="booklink" source-id="gene" document-id="pds" document-type="chapter">pyridoxine-dependent seizures</related-object> [<xref ref-type="bibr" rid="pbd.REF.plecko.2000.121">Plecko et al 2000</xref>] and in individuals with psychomotor retardation who have normal levels of other peroxisomal metabolites [<xref ref-type="bibr" rid="pbd.REF.baas.2002.699">Baas et al 2002</xref>]. Thus, isolated elevation of plasma concentration of pipecolic acid is not necessarily indicative of a primary defect in peroxisomal metabolism.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Peroxisomal mosaicism.</bold> An issue in interpreting biochemical test results is peroxisomal mosaicism. Nomenclature for describing peroxisomal mosaicism has not been established, but data support the presence of two main subtypes (type 1 and type 2) of peroxisomal mosaicism. Type 1 and type 2 peroxisomal mosaicism may be observed in the same individual.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Type 1.</bold> A disparity is found between biochemical or cellular results obtained in blood, cultured fibroblasts, or liver (or other tissue) from the same individual. Thus, plasma VLCFA concentration may be increased while fibroblast VLCFA content is normal. Type 1 peroxisomal mosaicism has been reported in an individual with PEX6 deficiency [<xref ref-type="bibr" rid="pbd.REF.pineda.1999.434">Pineda et al 1999</xref>, <xref ref-type="bibr" rid="pbd.REF.depreter.2003.203">Depreter et al 2003</xref>]. More recently, it has been shown that individuals with PEX12 deficiency and p.Ser320Phe homozygosity have type 1 mosaicism when fibroblasts are cultured at 37&#x000b0; C, but when challenged at 40&#x000b0; C, defects in peroxisome assembly can be detected by immunocytochemistry [<xref ref-type="bibr" rid="pbd.REF.gootjes.2004.130">Gootjes et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Type 2.</bold> A disparity is found in the matrix protein import in peroxisomes in adjacent cells from the same tissue specimen or culture from the same individual. Specifically, some fibroblasts may import catalase or other PTS1 and PTS2 proteins while other fibroblasts do not. One to ten percent of hepatocytes may have peroxisomal structures not observed in the majority of hepatocytes. Type 2 peroxisomal mosaicism has been reported in individuals with a milder phenotype and <italic toggle="yes">PEX1</italic>, <italic toggle="yes">PXMP3</italic> (<italic toggle="yes">PEX2</italic>), and <italic toggle="yes">PEX6</italic> pathogenic variants [<xref ref-type="bibr" rid="pbd.REF.pineda.1999.434">Pineda et al 1999</xref>, <xref ref-type="bibr" rid="pbd.REF.shimozawa.2000.31">Shimozawa et al 2000</xref>, <xref ref-type="bibr" rid="pbd.REF.weller.2000.247">Weller et al 2000</xref>].</p>
            </list-item>
          </list>
          <p><bold>Complementation analysis.</bold> Complementation analyses allow one to infer which gene is defective. Classic complementation analysis relies on somatic cell hybridization and biochemical assay [<xref ref-type="bibr" rid="pbd.REF.moser.1995.13">Moser et al 1995</xref>] or cDNA complementation analysis followed by immunocytochemical analysis.</p>
          <sec id="pbd.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Genes.</bold> Pathogenic variants in twelve different <italic toggle="yes">PEX</italic> genes &#x02013; those that encode peroxins, the proteins required for normal peroxisome assembly &#x02013; have been identified in PBD, ZSS (<xref ref-type="table" rid="pbd.T.summary_of_molecular_genetic_testi">Table 2</xref>) [<xref ref-type="bibr" rid="pbd.REF.gould.2001">Gould et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.matsumoto.2003.233">Matsumoto et al 2003</xref>, <xref ref-type="bibr" rid="pbd.REF.shimozawa.2004.552">Shimozawa et al 2004</xref>].</p>
            <p><bold>Other loci.</bold> As of now there is no evidence that mutation of any other <italic toggle="yes">PEX</italic> genes is associated with ZSS disorders. Although <xref ref-type="bibr" rid="pbd.REF.ebberink.2011.59">Ebberink et al [2011]</xref> reported that 100% of fibroblast cell lines from 613 affected individuals had an identifiable pathogenic variant involving <italic toggle="yes">PEX1</italic>, <italic toggle="yes">2</italic>, <italic toggle="yes">3</italic>, <italic toggle="yes">5</italic>, <italic toggle="yes">6</italic>, <italic toggle="yes">10</italic>, <italic toggle="yes">12</italic>, <italic toggle="yes">13</italic>, <italic toggle="yes">14</italic>, <italic toggle="yes">16</italic>, <italic toggle="yes">19,</italic> or <italic toggle="yes">26</italic>, it is nonetheless possible that pathogenic variants in other genes not detected using currently available methods cause milder or different biochemical and clinical phenotypes.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <p><bold><italic toggle="yes">PEX1</italic></bold> mutation is the most common cause of PBD, ZSS, associated with about 68% of all affected individuals. Two common <italic toggle="yes">PEX1</italic> pathogenic variants have been identified: <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants">p.Ile700TyrfsTer42</xref> (in exon 13) and <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants">p.Gly843Asp</xref> (in exon 15). About 80% of individuals with a <italic toggle="yes">PEX1</italic> defect have at least one of these two common alleles [<xref ref-type="bibr" rid="pbd.REF.collins.1999.45">Collins &#x00026; Gould 1999</xref>, <xref ref-type="bibr" rid="pbd.REF.walter.2001.35">Walter et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.maxwell.2002.342">Maxwell et al 2002</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Sequence analysis of the coding region and associated splice sites of PEX1 detects these common pathogenic variants and virtually all other pathogenic variants.</p>
              </list-item>
              <list-item>
                <p>Sequence analysis of PEX1 exons 13 and 15, where the common pathogenic variants <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.Ile700TyrfsTer42</underline></xref> and <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.Gly843Asp</underline></xref> are located, respectively, identifies at least one of these common pathogenic variants or a previously unknown pathogenic variant in slightly more than 50% of individuals with PBD, ZSS [<xref ref-type="bibr" rid="pbd.REF.gould.2001">Gould et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>
                <italic toggle="yes">PEX6, PEX26, PEX10, PEX12</italic>
              </bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Sequence analysis or sequence analysis of select exons. Pathogenic variants in PEX6, PEX10, PEX12, and PEX26 account for another 26% of all individuals with PBD, ZSS (<xref ref-type="table" rid="pbd.T.summary_of_molecular_genetic_testi">Table 2</xref>).</p>
                <p>In conjunction with <italic toggle="yes">PEX1</italic> defects, more than 90% of all affected individuals have a defect in one of these five <italic toggle="yes">PEX</italic> genes.</p>
                <p>Sequence analysis of <italic toggle="yes">PEX1</italic> exons 13 and 15, <italic toggle="yes">PXMP3</italic> (<italic toggle="yes">PEX2</italic>) exon 4, <italic toggle="yes">PEX10</italic> exons 4 and 5, <italic toggle="yes">PEX12</italic> exons 2 and 3, and <italic toggle="yes">PEX26</italic> exons 2 and 3 detects about 72% of pathogenic alleles of PBD, ZSS [<xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>].</p>
                <p>Recurrent pathogenic variants have been described, including the <italic toggle="yes">PEX10</italic> variant <xref ref-type="table" rid="pbd.T.selected_pex10_pathogenic_variants">c.814_815delCT</xref> in the Japanese population.</p>
              </list-item>
            </list>
            <p>
              <bold><italic toggle="yes">PXMP3</italic> (<italic toggle="yes">PEX2</italic>)<italic toggle="yes">, PEX3, PEX5, PEX13, PEX14, PEX16, PEX19</italic></bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Sequence analysis. Pathogenic variants in PXMP3 (PEX2), PEX3, PEX5, PEX13, PEX14, PEX16, and PEX19 account for only about 6% of all individuals with PBD, ZSS.</p>
              </list-item>
            </list>
            <table-wrap id="pbd.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of PBD, ZSS Attributed to Mutation of This Gene</th>
                    <th id="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX1</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">68%&#x000a0;<sup>4</sup>; 58%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>4</sup> of exons 13,15,18 &#x00026; 19&#x000a0;<sup>8,&#x000a0;9</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for known variants in select exons</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX6</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">10.7%&#x000a0;<sup>4</sup>; 16%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup> of exon 1&#x000a0;<sup>8,&#x000a0;9</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in select exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for known variants in select exons</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX26</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">6.6%&#x000a0;<sup>4</sup>; 3%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup> of exons 2 and 3&#x000a0;<sup>8,&#x000a0;9</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in select exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for known variants in select exons</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX10</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">4.6%&#x000a0;<sup>4</sup>; 3%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup> of exons 4 and 5&#x000a0;<sup>8,&#x000a0;9</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in select exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for known variants in select exons</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX12</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">4.1%&#x000a0;<sup>4</sup>; 9%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup> of exons 2 and 3&#x000a0;<sup>8,&#x000a0;9</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in select exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for variants in select exons&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PXMP3 (PEX2)</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">1%&#x000a0;<sup>4</sup>; 4%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup> of the one coding exon&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in select exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">100% for variants in select exons&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX3</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.5%&#x000a0;<sup>4</sup>; &#x0003c;1%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX5</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.5%&#x000a0;<sup>4</sup>; 2%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX13</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1%&#x000a0;<sup>4</sup>; 1%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX14</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.5%&#x000a0;<sup>4,&#x000a0;11</sup>; &#x0003c;1%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX16</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.5%&#x000a0;<sup>4</sup>; 1%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PEX19</italic>
                    </td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.5%&#x000a0;<sup>4</sup>; &#x0003c;1%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>6</sup> of all coding exons</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pbd.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>7</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="pbd.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="pbd" object-id="pbd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="pbd.TF.2.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="pbd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="pbd.TF.2.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
                </fn>
                <fn id="pbd.TF.2.4">
                  <label>4. </label>
                  <p>Based on the experience at the Kennedy Krieger Institute using complementation analysis on a total of 197 individuals with biochemically demonstrated PBD, ZSS, except <italic toggle="yes">PEX14</italic> (see footnote 11)</p>
                </fn>
                <fn id="pbd.TF.2.5">
                  <label>5. </label>
                  <p><xref ref-type="bibr" rid="pbd.REF.ebberink.2011.59">Ebberink et al [2011]</xref> (613 patient fibroblast cell lines studied)</p>
                </fn>
                <fn id="pbd.TF.2.6">
                  <label>6. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="pbd.TF.2.7">
                  <label>7. </label>
                  <p>An estimate, based on the assumption that large deletions or promoter and deep intronic pathogenic variants would be missed; however, these types of pathogenic variants do not appear to be common in PBD, ZSS.</p>
                </fn>
                <fn id="pbd.TF.2.8">
                  <label>8. </label>
                  <p>Exons sequenced and detection rates may vary by laboratory.</p>
                </fn>
                <fn id="pbd.TF.2.9">
                  <label>9. </label>
                  <p>Sequence analysis of <italic toggle="yes">PEX1</italic> exons 13, 15, 18, and 19; <italic toggle="yes">PXMP3</italic> (<italic toggle="yes">PEX2</italic>) exon 4; <italic toggle="yes">PEX6</italic> exon 1; <italic toggle="yes">PEX10</italic> exons 4 and 5; <italic toggle="yes">PEX12</italic> exons 2 and 3; and <italic toggle="yes">PEX26</italic> exons 2 and 3 detects about 79% of PBD, ZSS-causing alleles [<xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>].</p>
                </fn>
                <fn id="pbd.TF.2.10">
                  <label>10. </label>
                  <p><italic toggle="yes">PXMP3</italic> has only one coding exon.</p>
                </fn>
                <fn id="pbd.TF.2.11">
                  <label>11. </label>
                  <p>Pathogenic variants in <italic toggle="yes">PEX14</italic> were identified in one individual with PBD, ZSS by <xref ref-type="bibr" rid="pbd.REF.shimozawa.2004.552">Shimozawa et al [2004]</xref>; thus, <italic toggle="yes">PEX14</italic> was not a recognized complementation group when studies were performed at Kennedy Krieger Institute.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="pbd.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> Biochemical abnormalities detected in blood and/or urine should be confirmed in cultured fibroblasts.</p>
          <p>In some individuals, liver biopsy may be necessary.</p>
          <p><bold><italic toggle="yes">PEX</italic> molecular genetic testing algorithm.</bold> To circumvent the need for complementation studies, which require cultured fibroblasts, two slightly different algorithms for analysis of a subset of <italic toggle="yes">PEX</italic> exons have been developed:</p>
          <list list-type="bullet">
            <list-item>
              <p>The variant detection frequency of sequence analysis of PEX1 exons 13, 15, and 18, PEX2 exon 4, PEX6 exon 1, PEX10 exons 3-5, PEX12 exons 2 and 3, and PEX26 exons 2 and 3 is 79% [<xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>The detection frequency for at least one pathogenic variant of sequence analysis of PEX1 exons 13 and 15, PEX2 exon 4, PEX10 exons 4 and 5, PEX12 exons 2 and 3, and PEX26 exons 2 and 3 is approximately 72%.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family. Prenatal diagnosis by biochemical testing is also possible; ideally, the biochemical defects in cultured fibroblasts from an affected family member should be confirmed first.</p>
        </sec>
      </sec>
      <sec id="pbd.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pbd.Clinical_Description">
          <title>Clinical Description</title>
          <p>Peroxisome biogenesis disorders, Zellweger syndrome spectrum (PBD, ZSS) are defined by a continuum of three phenotypes described before the biochemical and molecular bases of these disorders had been fully determined: Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD) and infantile <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object> (IRD) [<xref ref-type="bibr" rid="pbd.REF.gould.2001">Gould et al 2001</xref>].</p>
          <p>All of the peroxisome assembly disorders are serious disorders, frequently resulting in death in childhood. ZS is the most severe and IRD the least severe of these phenotypes. The generalizations that these labels represent are still useful when facing undiagnosed individuals and counseling their families, but one should not place too much emphasis on assigning an affected individual to one of these categories. Because of the breadth of phenotypic variation, individuals with PBD, ZSS mainly come to clinical attention in the newborn period or later in childhood. Occasionally, the subtlety of symptoms delays diagnosis until adulthood.</p>
          <p>In the <bold>newborn period</bold>, affected children are hypotonic with resultant poor feeding. Neonatal seizures are frequent. Liver dysfunction may be evident as neonatal jaundice and elevation in liver function tests. Distinctive craniofacial features include flattened facies, large anterior fontanelle, widely split sutures, and broad nasal bridge. In severely affected children, bony stippling (chondrodysplasia punctata) at the patella(e) and other long bones may be noted.</p>
          <p><bold>Older children</bold> manifest retinal dystrophy, sensorineural hearing loss, developmental delay with hypotonia, and liver dysfunction. Children may first come to attention because of a failed hearing screen. Onset and severity of the hearing and visual problems are variable, but a peroxisome biogenesis disorder should be considered in any individual who manifests both conditions. A few children with a clinical diagnosis of neonatal adrenoleukodystrophy had transient leopard spot pigmentary retinopathy [<xref ref-type="bibr" rid="pbd.REF.lyons.2004.191">Lyons et al 2004</xref>]. Liver dysfunction may be first identified in children with severe bleeding episodes caused by a vitamin K-responsive coagulopathy. Older children may develop adrenal insufficiency.</p>
          <p>It is rare for an individual with PBD, ZSS to present as an adult, but instances of individuals presenting initially with predominantly sensory deficits have been reported [<xref ref-type="bibr" rid="pbd.REF.moser.1995.13">Moser et al 1995</xref>]. See the example of PEX6 deficiency (<xref ref-type="sec" rid="pbd.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</xref>).</p>
          <p><bold>Zellweger syndrome</bold> is characterized by presentation in the neonatal period with profound hypotonia, characteristic facies, seizures, inability to feed, liver cysts with hepatic dysfunction, and chondrodysplasia punctata. Infants with this condition are significantly impaired and usually die during the first year of life, usually having made no developmental progress. Death is usually secondary to progressive apnea or respiratory compromise from infection.</p>
          <p><bold>Neonatal adrenoleukodystrophy</bold> and <bold>infantile Refsum disease</bold> may present in the newborn period, but generally come to attention later because of developmental delays, hearing loss, or visual impairment. Liver dysfunction may lead to a vitamin K-responsive coagulopathy. Children have also come to attention with episodes of hemorrhage, and several children have presented in the first year of life with intracranial bleeding. The clinical course is variable; while many children are very hypotonic, many learn to walk and talk. The condition is often slowly progressive with hearing and vision worsening with time. Some individuals may develop progressive degeneration of the myelin, a leukodystrophy, which may lead to loss of previously acquired skills and ultimately death. Children who survive the first year and who have a non-progressive course have a 77% probability of reaching school age [<xref ref-type="bibr" rid="pbd.REF.pollthe.2004.333">Poll-The et al 2004</xref>].</p>
          <p><bold>Neuroimaging.</bold> Magnetic resonance imaging studies may identify hypomyelination, cortical gyral abnormalities, and germinolytic cysts that are highly suggestive of Zellweger syndrome [<xref ref-type="bibr" rid="pbd.REF.barkovich.1997.1163">Barkovich &#x00026; Peck 1997</xref>].</p>
          <p>More recent studies in a small number of individuals with PBD, ZSS have shown that diffusion-weighted imaging and diffusion tensor imaging can be used to discern white matter damage not detected by standard imaging [<xref ref-type="bibr" rid="pbd.REF.ter_rahe.2004.1022">ter Rahe et al 2004</xref>].</p>
        </sec>
        <sec id="pbd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Pathogenic variants in the two most commonly involved genes, <italic toggle="yes">PEX1</italic> and <italic toggle="yes">PEX6</italic>, are associated with the full continuum of clinical phenotypes. This clinical variability, in general, is also found in individuals with pathogenic variants in <italic toggle="yes">PEX10</italic>, <italic toggle="yes">PEX12</italic>, and <italic toggle="yes">PEX26</italic>.</p>
          <p><italic toggle="yes">PEX3</italic>, <italic toggle="yes">PEX16</italic>, and <italic toggle="yes">PEX19</italic> pathogenic variants, described in only one or two individuals, are associated exclusively with the most severe phenotype (ZS). Pathogenic variants in these three genes cause a cellular phenotype detected by immunocytochemical analysis. Peroxisomal membrane formation is completely absent in cell lines from these individuals.</p>
          <p>No direct association exists between the biochemical phenotype and the <italic toggle="yes">PEX</italic> pathogenic variant. Thus, it is not possible to identify the candidate gene based solely on the biochemical phenotype. However, a report suggests that two biochemical findings (DHAP-AT and C26:0 &#x003b2;-oxidation activity) are predictors of survival in individuals with PBD, ZSS [<xref ref-type="bibr" rid="pbd.REF.gootjes.2002.1746">Gootjes et al 2002</xref>].</p>
          <p>A general relationship appears to exist among the genotype, cellular phenotype (i.e., import of peroxisomal matrix proteins), and clinical phenotype [<xref ref-type="bibr" rid="pbd.REF.moser.1999.316">Moser 1999</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Frameshift variants are associated with more severe defects in peroxisome assembly and, consequently with more severe clinical phenotypes.</p>
            </list-item>
            <list-item>
              <p>Homozygosity for the PEX1 <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.Ile700TyrfsTer42</underline></xref> common allele is associated with a more severe phenotype.</p>
            </list-item>
            <list-item>
              <p>Compound heterozygosity for PEX1 alleles p.Ile700TyrfsTer42 and <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.Gly973AlafsTer16</underline></xref> also appears on the more severe end of the clinical spectrum. Cells from such individuals also have more severe defects in the import of peroxisomal matrix proteins.</p>
            </list-item>
            <list-item>
              <p>In contrast, the PEX1 <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.Gly843Asp</underline></xref> allele has been associated with the less severe end of the phenotypic clinical continuum and peroxisomal matrix protein import is nearer to normal.</p>
            </list-item>
            <list-item>
              <p>Homozygosity for PEX1 p.Gly843Asp has thus far been associated with a milder phenotype, usually IRD but sometimes NALD. Differences in the clinical picture within the same family are reported in compound heterozygotes for PEX1 <xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants"><underline>p.[Gly843Asp]+ [Ile700TyrfsTer42]</underline></xref>. Thus, other factors must contribute to developmental outcome and survival [<xref ref-type="bibr" rid="pbd.REF.pollthe.2004.333">Poll-The et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Homozygosity for PEX12 <xref ref-type="table" rid="pbd.T.selected_pex12_pathogenic_variants"><underline>p.Ser320Phe</underline></xref> is associated with type 1 mosaicism and the milder end of the clinical spectrum [<xref ref-type="bibr" rid="pbd.REF.gootjes.2004.130">Gootjes et al 2004</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="pbd.Nomenclature">
          <title>Nomenclature</title>
          <p>Peroxisome biogenesis disorders (PBD) can be divided into two subtypes: the Zellweger syndrome spectrum and the rhizomelic chondrodysplasia punctata spectrum, of which <related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter">RCDP1</related-object> is one subtype.</p>
          <p>Individuals with RCDP1 have pathogenic variants in <italic toggle="yes">PEX7</italic>, a receptor that recognizes peroxisomal enzymes containing peroxisomal targeting signal 2. Although individuals with RCDP1 have a perturbation in matrix protein import consistent with a peroxisomal assembly defect, they have a biochemical, cellular, and clinical phenotype distinct from PBD, Zellweger syndrome spectrum. (See <related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter">Rhizomelic Chondrodysplasia Punctata Type 1</related-object> for an in-depth description.)</p>
          <p>PBD, ZSS may also be referred to as cerebrohepatorenal syndrome, generalized peroxisomal disorders, Zellweger syndrome, neonatal adrenoleukodystrophy, or infantile Refsum disease (also known as infantile phytanic acid oxidase deficiency) . Some individuals later shown to have PBD, ZSS were initially described as having hyperpipcolatemia.</p>
          <p>Note: Infantile Refsum disease and <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object> are distinct clinical entities with different molecular basis (see <xref ref-type="sec" rid="pbd.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
        </sec>
        <sec id="pbd.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of PBD, ZSS is estimated at 1:50,000 [<xref ref-type="bibr" rid="pbd.REF.gould.2001">Gould et al 2001</xref>].</p>
          <p>These disorders occur worldwide, although variation is observed among populations. The main diagnostic center for peroxisomal diseases in Japan reported only 31 Japanese individuals over a 20-year period, with an estimated birth prevalence of only 1:500,000 [<xref ref-type="bibr" rid="pbd.REF.shimozawa.2003.40">Shimozawa et al 2003</xref>].</p>
        </sec>
      </sec>
      <sec id="pbd.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>The PBD, ZSS phenotypic spectrum is broad; some affected individuals have mild symptoms, mainly sensory deficits and/or mild developmental delay.</p>
        <p>Both parents of a boy who died of a PBD, ZSS at age 17 months had retinitis pigmentosa and sensorineural hearing loss, leading to the suspicion of <related-object link-type="booklink" source-id="gene" document-id="usher1" document-type="chapter">Usher syndrome type I</related-object> or <related-object link-type="booklink" source-id="gene" document-id="usher2" document-type="chapter">Usher syndrome type II</related-object>. However, biochemical analysis demonstrated that the parents had increased VLCFA and branched-chain fatty acids in plasma and deficiencies of &#x003b2;-oxidation, plasmalogen synthesis, and peroxisome assembly in cultured fibroblasts. Complementation studies for the parents and the affected boy were consistent with a PEX6 deficiency. The affected child had the <italic toggle="yes">PEX6</italic> pathogenic variants <xref ref-type="table" rid="pbd.T.selected_pex6_pathogenic_variants">p.Thr572Ile</xref> and <xref ref-type="table" rid="pbd.T.selected_pex6_pathogenic_variants">c.2094+2T&#x0003e;C</xref>. The father was homozygous for one <italic toggle="yes">PEX6</italic> allele (p.Thr572Ile) and the mother was compound heterozygous for a splice-site variant (c.2094+2T&#x0003e;C) and two missense variants on the other <italic toggle="yes">PEX6</italic> allele (<xref ref-type="table" rid="pbd.T.selected_pex6_pathogenic_variants">p.Ala809Val</xref> and <xref ref-type="table" rid="pbd.T.selected_pex6_pathogenic_variants">p.Ile845Thr</xref>) [<xref ref-type="bibr" rid="pbd.REF.raasrothschild.2002.1062">Raas-Rothschild et al 2002</xref>].</p>
      </sec>
      <sec id="pbd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses vary with the age of presentation and most prominent feature of presentation.</p>
        <p>PBD, ZSS in newborns is most often confused with other conditions that result in profound hypotonia including Down syndrome, other chromosomal abnormalities, <related-object link-type="booklink" source-id="gene" document-id="pws" document-type="chapter">Prader-Willi syndrome</related-object>, <related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">spinal muscular atrophy</related-object>, congenital <related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">myotonic dystrophy type 1</related-object>, and congenital myopathies such as <related-object link-type="booklink" source-id="gene" document-id="mtm" document-type="chapter">X-linked myotubular myopathy</related-object> and <related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter">multiminicore myopathy</related-object>.</p>
        <p>Older children have been initially presumed to have <related-object link-type="booklink" source-id="gene" document-id="usher1" document-type="chapter">Usher syndrome type I</related-object> or <related-object link-type="booklink" source-id="gene" document-id="usher2" document-type="chapter">Usher syndrome type II</related-object> and other disorders of sensorineural hearing loss and retinitis pigmentosa, <related-object link-type="booklink" source-id="gene" document-id="lca" document-type="chapter">Leber congenital amaurosis</related-object> [<xref ref-type="bibr" rid="pbd.REF.lambert.1989.624">Lambert et al 1989</xref>, <xref ref-type="bibr" rid="pbd.REF.michelakakis.2004.146">Michelakakis et al 2004</xref>] (see also <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Hearing Loss and Deafness Overview</related-object> and <related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter">Retinitis Pigmentosa Overview</related-object>), <related-object link-type="booklink" source-id="gene" document-id="cockayne" document-type="chapter">Cockayne syndrome</related-object>, or congenital infections. Leukodystrophies may result from lysosomal storage diseases including <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object> and metachromatic leukodystrophy (see <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">Arylsulfatase A Deficiency</related-object>) or mitochondrial disease (see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Diseases Overview</related-object>) and often are the first consideration.</p>
        <p>At least 15% of individuals presenting with a clinical phenotype in the Zellweger syndrome spectrum and demonstrating increased plasma VLCFA concentration actually have a single-enzyme deficiency of peroxisomal &#x003b2;-oxidation (i.e., D-bifunctional enzyme deficiency or acyl-CoA oxidase deficiency) and do not have a pathogenic variant in a <italic toggle="yes">PEX</italic> gene. Diagnosis of these disorders is possible by biochemical testing (<xref ref-type="table" rid="pbd.T.testing_to_distinguish_pbd_zss_fro">Table 3</xref>).</p>
        <list list-type="bullet">
          <list-item>
            <p>D-bifunctional enzyme deficiency is more common and in general more severe, often presenting with severe seizures within the first days of life; thus, it more closely resembles ZS.</p>
          </list-item>
          <list-item>
            <p>Acyl-CoA oxidase deficiency has a less pronounced biochemical and clinical phenotype and in general follows a disease course more similar to NALD (see <xref ref-type="bibr" rid="pbd.REF.watkins.1995.472">Watkins et al [1995]</xref> for comparison of the two).</p>
          </list-item>
        </list>
        <p>It is important to differentiate peroxisome assembly defects from other single-enzyme defects of peroxisomal metabolism. Children may be erroneously diagnosed as having a variant of <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> or adult <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object>. This most often occurs secondary to lack of familiarity with the underlying defect and the unfortunate redundancy of eponyms.</p>
        <list list-type="bullet">
          <list-item>
            <p>X-linked adrenoleukodystrophy is characterized by an elevation of plasma concentrations of VLCFAs without other abnormalities of peroxisomes. Males with this condition are almost always developmentally normal before their initial presentation.</p>
          </list-item>
          <list-item>
            <p>Adult Refsum disease is caused by pathogenic variants in <italic toggle="yes">PHYH</italic>, the gene that encodes phytanoyl-CoA hydroxylase, in more than 90% of affected individuals, and pathogenic variants in <italic toggle="yes">PEX7</italic>, the gene that encodes the PTS2 receptor, in fewer than 10% of affected individuals. Individuals with adult Refsum disease have a biochemical profile distinct from PBD, ZSS and are developmentally normal before presenting in their late teens or twenties.</p>
          </list-item>
        </list>
        <p>An increase in plasma VLCFA concentration consistent with a defect in peroxisomal fatty acid metabolism could be associated with four main disease types: (1) PBD, ZSS; (2) a single-enzyme deficiency (SED) of the peroxisomal &#x003b2;-oxidation enzymes D-bifunctional protein (D-BP) or acyl-CoA oxidase (AOx) [<xref ref-type="bibr" rid="pbd.REF.watkins.1995.472">Watkins et al 1995</xref>]; (3) <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD) or adrenomyeloneuropathy (AMN), caused by pathogenic variants in <italic toggle="yes">ABCD1</italic>; and (4) CADDS, a contiguous deletion syndrome with a critical region spanning <italic toggle="yes">ABCD1</italic> and <italic toggle="yes">BAP31</italic> [<xref ref-type="bibr" rid="pbd.REF.corzo.2002.1520">Corzo et al 2002</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>An increase in plasma concentration of C26:1 is not observed in X-ALD; however, individuals with CADDS have a VLCFA profile very similar to that seen in individuals with PBD.</p>
          </list-item>
          <list-item>
            <p>X-ALD and AMN are clinically distinct (see <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-ALD</related-object>) from these other disorders, and the biochemical findings should not cause any diagnostic quandaries. In contrast, the clinical phenotypes for PBD, SED, and CADDS overlap and can only be distinguished by further testing of blood and cultured fibroblasts (<xref ref-type="table" rid="pbd.T.testing_to_distinguish_pbd_zss_fro">Table 3</xref>). In an individual with increased plasma VLCFA concentration and a phenotype consistent with a PBD, a fibroblast cell line established from a skin biopsy can be helpful in completing the diagnostic evaluation. Individuals with a PBD do not necessarily have a classic biochemical phenotype. Thus, the full array of studies listed in <xref ref-type="table" rid="pbd.T.testing_to_distinguish_pbd_zss_fro">Table 3</xref> may be required to determine whether an individual has a PBD or SED. In some individuals, complementation studies and/or molecular analysis may be required to establish that an atypical biochemical phenotype is consistent with the diagnosis of PBD, ZSS. Occasionally, when the enzymatic defects that should correspond to the abnormalities observed in blood and urine are not detected in cultured fibroblasts, analysis of skin biopsies from other sites or a liver biopsy may help detect peroxisomal mosaicism.</p>
          </list-item>
        </list>
        <table-wrap id="pbd.T.testing_to_distinguish_pbd_zss_fro" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Testing to Distinguish PBD, ZSS from a Single-Enzyme Deficiency or CADDS</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1"/>
                <th id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2">PBD, ZSS</th>
                <th id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Single-Enzyme Deficiency</th>
                <th id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4">CADDS</th>
              </tr>
              <tr>
                <th headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3" id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">D-Bifunctional Protein Deficiency</th>
                <th headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3" id="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Acyl-CoA Oxidase Deficiency</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Plasma Concentrations</bold>
                </td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">VLCFA</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phytanic acid</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal to increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal to increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Bile acids</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">THCA/DHCA present</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">THCA/DHCA present</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Increased amount</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Urine Concentrations</bold>
                </td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Pipecolic acid</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal to increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Epoxydicarboxylic acids</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Present to absent</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Present to absent</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Present to absent</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Absent</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Bile acids</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">THCA/DHCA present</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">THCA/DHCA present</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Increased amount</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Erythrocyte Membranes</bold>
                </td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Plasmalogens</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient to normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Fibroblasts, Cultured</bold>
                </td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">VLCFA concentrations</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">VLCFA -oxidation</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Plasmalogen synthesis</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient to normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">DHAP-AT activity</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient to normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">ADHAP-S activity</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient to normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phytanic acid oxidation</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Pristanic acid oxidation</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Deficient</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Catalase solubility</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Immunohistochemistry</bold>
                </td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Peroxisome structure</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Absent to enlarged &#x00026; reduced in number</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Enlarged &#x00026; reduced in number</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Enlarged &#x00026; reduced in number</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Catalase import</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Absent to partial</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_3 hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                <td headers="hd_h_pbd.T.testing_to_distinguish_pbd_zss_fro_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>DHCA = dihydroxycholestanoic acid</p>
            </fn>
            <fn>
              <p>THCA = trihydroxycholestanoic acid</p>
            </fn>
            <fn>
              <p>DHAP-AT = dihydroxyacetone phosphate-acyl transferase</p>
            </fn>
            <fn>
              <p>ADHAP-S = alkyl-dihydroxyacetone phosphate synthase</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold><italic toggle="yes">DLP1</italic></bold> (dynamin-like protein 1 gene). In one report a dominant-negative heterozygous pathogenic variant (p.Ala395Asp) was detected in an infant girl, but not in either parent [<xref ref-type="bibr" rid="pbd.REF.waterham.2007.1736">Waterham et al 2007</xref>]. Clinical findings were mild dysmorphic facial features, truncal hypotonia, absent tendon reflexes, microcephaly, optic atrophy, failure to thrive, and severe developmental delay. Biochemical findings included mildly elevated plasma VLCFA and persistent lactic acidemia. Immunocytochemical studies in cultured fibroblasts suggested a defect in mitochondrial and peroxisomal fission.</p>
      </sec>
      <sec id="pbd.Management">
        <title>Management</title>
        <sec id="pbd.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with peroxisome biogenesis disorders, Zellweger syndrome spectrum (PBD, ZSS), evaluations of the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Feeding</p>
            </list-item>
            <list-item>
              <p>Hearing</p>
            </list-item>
            <list-item>
              <p>Vision (comprehensive ophthalmologic assessment)</p>
              <p>Note: Electroretinogram (ERG) and visual field testing are useful in the diagnosis of retinal dystrophy.</p>
            </list-item>
            <list-item>
              <p>Liver function</p>
            </list-item>
            <list-item>
              <p>Neurologic function (possible MRI of the brain and EEG)</p>
            </list-item>
            <list-item>
              <p>Development</p>
            </list-item>
            <list-item>
              <p>Possible endocrine evaluation of adrenal function as adrenal insufficiency may occur during periods of stress</p>
            </list-item>
          </list>
        </sec>
        <sec id="pbd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment focuses on symptomatic therapy.</p>
          <p><bold>Feeding and nutrition.</bold> Supplying adequate calorie intake for affected children often entails the placement of a gastrostomy tube to allow simpler home management. No specific metabolic diet is recommended. With many children having some degree of malabsorption, elemental formulas may be better tolerated.</p>
          <p><bold>Hearing.</bold> Hearing aids should be used in children found to have hearing impairment. (See also <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Hearing Loss and Deafness Overview</related-object> for discussion of management issues.)</p>
          <p><bold>Vision.</bold> Cataract removal in early infancy to preserve vision is appropriate. Glasses should be used as needed to correct refractive errors.</p>
          <p><bold>Liver.</bold> Supplementation of vitamin K and other fat-soluble vitamins is recommended.</p>
          <p>Liver dysfunction may lead to varices that respond to sclerosing therapies.</p>
          <p>Primary bile acid therapy may improve liver function by reducing the accumulation of cholestanoic acids [<xref ref-type="bibr" rid="pbd.REF.setchell.1992.198">Setchell et al 1992</xref>].</p>
          <p><bold>Neurologic function.</bold> Early intervention services should be provided.</p>
          <p>Seizures are present in approximately one third of affected individuals. Standard antiepileptic drugs (AEDs) may be used. No type of AED is contraindicated. Seizures may be difficult to control despite use of appropriate medication.</p>
        </sec>
        <sec id="pbd.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>No curative therapy is presently available for PBD, ZSS.</p>
        </sec>
        <sec id="pbd.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Longer-surviving affected individuals should be monitored for hyperoxaluria, which can lead to stone formation and renal failure.</p>
        </sec>
        <sec id="pbd.Surveillance">
          <title>Surveillance</title>
          <p>Hearing should be evaluated annually.</p>
          <p>Annual ophthalmologic evaluation is indicated. (Although electroretinogram is useful in the diagnosis of a retinal dystrophy, it is not useful in follow up; visual field testing is much more helpful.)</p>
          <p>Coagulation factors and other synthetic liver functions should be monitored. Persons with overt hepatic dysfunction require more routine monitoring.</p>
          <p>The use of routine neuroimaging is uncertain. Individuals with peroxisomal disorders may develop a progressive leukodystrophy. No effective therapy exists, but identification of white matter changes may explain changes in cognitive and/or motor ability.</p>
        </sec>
        <sec id="pbd.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoidance of cow's milk and related products reduces exposure to phytanic acid.</p>
        </sec>
        <sec id="pbd.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="pbd.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pbd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>The use of docosahexaenoic acid (DHA) has been suggested as a treatment for PBD, ZSS. This compound, which is important in brain and retinal function, is low in PBD, ZSS.</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="bibr" rid="pbd.REF.martinez.2001.309">Martinez [2001]</xref> and <xref ref-type="bibr" rid="pbd.REF.noguer.2010.2277">Noguer &#x00026; Martinez [2010]</xref> have reported that DHA ethyl ester supplements restore DHA levels and improve liver function and visual function in some study participants, especially in those treated in the first six months of life.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="pbd.REF.paker.2010.826">Paker et al [2010]</xref> performed a double-blind placebo-controlled trial in 48 children with PBD, ZSS who were supplemented daily with 100 mg/kg of DHA. Over a one-year period this study found no benefit from DHA supplementation in the two outcome measures used: growth and visual function.</p>
            </list-item>
          </list>
          <p>Although no clinical trial has been performed, anecdotal evidence suggests that all patients with PBD, ZSS who are treated with DHA benefit from primary bile acid supplementation [<xref ref-type="bibr" rid="pbd.REF.setchell.1992.198">Setchell et al 1992</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="pbd.Other">
          <title>Other</title>
          <p>A diet low in phytanic acid has been proposed, based mainly on the weak analogy with adult <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object>, in which accumulation of phytanic acid is pathogenic and treatment involves restricted dietary intake of phytanic acid. Its effectiveness in PBD, ZSS has never been proven. All standard infant formulas are already low in phytanic acid.</p>
        </sec>
      </sec>
      <sec id="pbd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pbd.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>PBD, ZSS is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="pbd.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutated allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In general, affected individuals do not reproduce.</p>
            </list-item>
            <list-item>
              <p>Some individuals with milder phenotypes may reproduce; the offspring of such individuals are obligate heterozygotes (carriers).</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="pbd.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
          <p>Biochemical testing is not accurate for carrier testing as the biochemical markers in carriers are normal.</p>
        </sec>
        <sec id="pbd.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pbd.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>
            <bold>Biochemical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>It is important to confirm the biochemical defects in cultured fibroblasts from the proband, as the biochemical defects detected in body fluids or liver are not always apparent in cultured cells (i.e., type 1 peroxisomal mosaicism is present). Biochemical test sensitivity is slightly reduced in cases that have not been confirmed in fibroblasts from an index case because the biochemical phenotype is non-penetrant in cultured cells of a small number (&#x0003c;5%) of individuals with Zellweger spectrum disorder.</p>
            </list-item>
            <list-item>
              <p>Prenatal diagnosis may be more challenging technically when the biochemical diagnosis of PBD, ZSS in the index case was made using blood, but cultured skin fibroblasts did not demonstrate all of the corresponding defects (i.e., type 1 peroxisomal mosaicism was present). It is possible that the cultured cells derived from chorionic villi or amniocytes in a fetus with PBD, ZSS and type 1 peroxisomal mosaicism would not express the defect. Thus, biochemical and immunocytochemical methods not routinely used by a laboratory may be required to offer accurate prenatal diagnosis. For this reason, it is best to document deficiencies in the cultured fibroblasts from the index case before offering prenatal diagnosis using a given assay.</p>
            </list-item>
            <list-item>
              <p>Some individuals with PBD, ZSS have elevated VLCFA in cultured cells, but normal plasmalogen synthesis. Both VLCFA content and plasmalogen synthesis can be measured in cultured CVS or amniocytes. The growth conditions are critical for measurement of VLCFA content and should only be performed in a center that has examined numerous specimens. Reports of false negative results have been described in the literature [<xref ref-type="bibr" rid="pbd.REF.carey.1994.813">Carey et al 1994</xref>, <xref ref-type="bibr" rid="pbd.REF.gray.1995.486">Gray et al 1995</xref>].</p>
            </list-item>
            <list-item>
              <p>Bile acid metabolites can be quantitated in the amniotic fluid [<xref ref-type="bibr" rid="pbd.REF.stellaard.1991.353">Stellaard et al 1991</xref>].</p>
            </list-item>
            <list-item>
              <p>Immunocytochemical analysis of chorionic villus sampling (CVS) can be used as an adjunct to confirm that all cells have normal peroxisome morphology and import peroxisomal matrix proteins.</p>
            </list-item>
            <list-item>
              <p>Direct CVS can be assayed for DHAP-AT, one of the deficient enzymes required for plasmalogen synthesis [<xref ref-type="bibr" rid="pbd.REF.steinberg.1999.502">Steinberg et al 1999</xref>], and immunoblot analysis for &#x003b2;-oxidation enzymes [<xref ref-type="bibr" rid="pbd.REF.wanders.1995.101">Wanders et al 1995</xref>].</p>
            </list-item>
            <list-item>
              <p>It is important to perform studies to rule out maternal cell contamination (MCC) in cultured CVS [<xref ref-type="bibr" rid="pbd.REF.steinberg.2005.38">Steinberg et al 2005</xref>]. Because individuals heterozygous for <italic toggle="yes">PEX</italic> pathogenic variants do not have any biochemical phenotype, MCC could cause a false negative result in an affected fetus, but not a false positive result in a normal fetus. Based on cell mixing experiments, the authors estimate that MCC would probably need to be greater than 30% for VLCFA or plasmalogen synthesis results to be completely normalized, although the extent of the deficiency in the proband would need to be considered.</p>
            </list-item>
          </list>
          <p><bold>Molecular genetic testing.</bold> Once the pathogenic variants have been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for PBD, ZSS are possible.</p>
        </sec>
      </sec>
      <sec id="pbd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pbd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="pbd.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Pathogenic variants in the twelve genes listed in <xref ref-type="table" rid="pbd.T.structure_of_the_12_pex_genes_asso">Table 4</xref> are known to cause PBD, ZSS in humans. These genes encode proteins required for peroxisome biogenesis called "peroxins"; the nomenclature for naming the genes is <italic toggle="yes">"PEX"</italic> followed by a number. A few of the peroxins appear to be essential for peroxisome membrane formation. However, the majority of known affected individuals have pathogenic variants in <italic toggle="yes">PEX</italic> genes encoding proteins essential for the import of peroxisomal matrix proteins.</p>
          <p><bold>Peroxisomes: biogenesis and assembly.</bold> At least 29 peroxins are required for peroxisome membrane biogenesis, fission, and protein import to form competent organelles. Much of our understanding of the function of these peroxins stems from work performed in a variety of yeast strains. Thus far, pathogenic variants in 13 genes that encode peroxins are associated with human disease. The biogenesis of membranes is not well understood, but pathogenic variants in three human <italic toggle="yes">PEX</italic> genes (<italic toggle="yes">PEX3</italic>, <italic toggle="yes">PEX16</italic>, and <italic toggle="yes">PEX19</italic>) are associated with an absence of any peroxisome membrane structures [<xref ref-type="bibr" rid="pbd.REF.ghaedi.2000.976">Ghaedi et al 2000</xref>]. The remaining proteins encoded by known <italic toggle="yes">PEX</italic> genes contribute to the machinery required for matrix protein import, a complex process currently under active study. In general, peroxisomal matrix proteins are encoded by nuclear genes that are translated on free polyribosomes. <italic toggle="yes">PXR1</italic> (<italic toggle="yes">PEX5</italic>) encodes a receptor that recognizes proteins containing peroxisomal targeting sequence 1 (PTS1), defined by the carboxy terminal consensus sequence serine-lysine-leucine (SKL). <italic toggle="yes">PEX7</italic> encodes the PTS2 receptor and recognizes proteins with an N-terminal motif present in fewer matrix proteins. Pathogenic variants in <italic toggle="yes">PEX7</italic> are associated with the clinically distinct disorder <related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter">RCDP</related-object>. Two sub-complexes have been proposed to be anchored by Pex8p, which is associated with the more lumenal aspect of the peroxisomal membrane [<xref ref-type="bibr" rid="pbd.REF.agne.2003.635">Agne et al 2003</xref>]. The two sub-complexes comprise the proteins (1) PEX14, PEX17, and PEX13, and (2) PEX10, PEX12, and PEX2. The first sub-complex plays a role in the docking of the PTS1 and PTS2 receptors and their associated proteins and the second sub-complex appears to be part of the translocation apparatus for matrix proteins. In contrast, PEX1 and PEX6 form a complex that may play a role in the recycling of the receptors encoded by <italic toggle="yes">PEX5</italic> and <italic toggle="yes">PEX7</italic>. Epistasis studies in yeast indicate that PEX1, PEX6, PEX4 and PEX22 act late in the import pathway, perhaps after the translocation process [<xref ref-type="bibr" rid="pbd.REF.collins.2000.7516">Collins et al 2000</xref>]. However, the recent identification of <italic toggle="yes">PEX26</italic> has shown that the encoded protein directly interacts with PEX1-PEX6 complexes. Thus, all three proteins may play a critical role in the presentation of PTS1 and PTS2 proteins to the peroxisomal membrane.</p>
          <p><bold>Peroxisomes: metabolic pathways.</bold> A variety of anabolic and catabolic pathways occur in the peroxisome. &#x003b2;-oxidation and plasmalogen synthesis are two fundamental pathways localized there. The peroxisomal &#x003b2;-oxidation enzymes are distinct from the mitochondrial system. Straight-chain VLCFA &#x003b2;-oxidation requires the enzymes very-long-chain acyl CoA synthetase, acyl CoA oxidase, D-bifunctional protein (enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase), and peroxisomal &#x003b2;-ketothiolase. All of these proteins have PTS1 signals except for peroxisomal &#x003b2;-ketothiolase, which is imported in a proform via a PTS2 signal. These proteins also play an important role in the side-chain modification of C27-bile acids. Thus, the defect in peroxisomal fatty acid &#x003b2;-oxidation accounts for the increase in VLCFA branched-chain fatty acids such as pristanic acid, and C27-bile acids. A unique branched-chain acyl CoA oxidase is used for bile acids and pristanic acid, thus explaining why these metabolites are normal in acyl-CoA oxidase deficiency. The initial steps of plasmalogen synthesis occur in the peroxisome and the final stages of synthesis are completed in the endoplasmic reticulum. Dihydroxyacetone phosphate (DHAP)-acyl transferase and alkyl-DHAP-synthase are PTS1 and PTS2 proteins, respectively.</p>
          <p>It is not possible to determine the defective <italic toggle="yes">PEX</italic> gene based solely on the clinical, biochemical, or cellular phenotype. However, a good correlation often exists between the defective <italic toggle="yes">PEX</italic> gene, the type of pathogenic variant, the impact on peroxisome assembly, and the clinical severity.</p>
          <p>The online database <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.dbpex.org/home.php">www.dbpex.org/home.php</ext-link> chronicles pathogenic variants identified in the 13 <italic toggle="yes">PEX</italic> genes associated with human disease. Pathogenic variants are those reported in peer-reviewed manuscripts and those submitted by clinical laboratories.</p>
          <p>The impact of any <italic toggle="yes">PEX</italic> pathogenic variant can be assessed by evaluating the morphology of peroxisomes in cultured fibroblasts and their ability to import proteins with a PTS1 or PTS2 signal. Catalase is often used as a marker for PTS1 import, although an antibody to carboxy terminal -SKL is quite valuable for evaluating general PTS1 import. Antibodies to &#x003b2;-ketothiolase, phytanoyl CoA hydroxylase, or alkyl DHAP synthase can be used for evaluating PTS2 import. Individuals with <italic toggle="yes">PEX3</italic>, <italic toggle="yes">PEX16</italic>, or <italic toggle="yes">PEX19</italic> defects are likely to lack any peroxisomal membrane remnants, detected by immunostaining peroxisomal membrane proteins such as ALDP or PMP70. In contrast, individuals with other <italic toggle="yes">PEX</italic> gene defects are likely to have peroxisomes that can be visualized if a peroxisomal membrane protein antibody is used. However, these peroxisomal structures are likely to be enlarged in size and reduced in number. The type of pathogenic variant(s) in the particular <italic toggle="yes">PEX</italic> gene determines the impact on PTS1 and PTS2 import. A large number of cells need to be evaluated to assess the impact on import. PTS1 or PTS2 import may be completely absent in an individual with ZS and only minimally impaired in an individual on the milder end of the clinical spectrum [<xref ref-type="bibr" rid="pbd.REF.shimozawa.1999a.779">Shimozawa et al 1999a</xref>].</p>
          <p>Careful immunocytochemical analysis in fibroblasts that are deficient in a variety of <italic toggle="yes">PEX</italic> genes (<italic toggle="yes">PEX6</italic>, <italic toggle="yes">PEX5</italic>, <italic toggle="yes">PEX26</italic>, <italic toggle="yes">PEX1</italic>, <italic toggle="yes">PXMP3</italic> [<italic toggle="yes">PEX2</italic>], <italic toggle="yes">PEX13</italic>) has resulted in the identification of a phenomenon called "temperature sensitivity" [<xref ref-type="bibr" rid="pbd.REF.imamura.1998.2089">Imamura et al 1998</xref>, <xref ref-type="bibr" rid="pbd.REF.shimozawa.1999b.1077">Shimozawa et al 1999b</xref>, <xref ref-type="bibr" rid="pbd.REF.imamura.2000.541">Imamura et al 2000</xref>, <xref ref-type="bibr" rid="pbd.REF.ito.2001.321">Ito et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.akiyama.2002.1523">Akiyama et al 2002</xref>, <xref ref-type="bibr" rid="pbd.REF.matsumoto.2003.233">Matsumoto et al 2003</xref>]. PEX-deficient fibroblasts incubated at 37&#x000b0;C may have a more severe cellular phenotype based on PTS1 and PTS2 import than cell lines cultured at 30&#x000b0;C. Since this phenomenon has been described in cell lines with pathogenic missense variants, it has been hypothesized that culturing the cells at a lower temperature allows the mutated protein to attain a more relaxed conformation that enhances function. The identification of small molecules in vivo that would mimic the effect of lowering incubation temperature may have therapeutic relevance. Similarly, culturing cells at 40&#x000b0;C can be used to exacerbate the defect in cells exhibiting a milder import phenotype. This may be particularly useful for cells exhibiting mosaicism [<xref ref-type="bibr" rid="pbd.REF.gootjes.2003.107">Gootjes et al 2003</xref>].</p>
          <table-wrap id="pbd.T.structure_of_the_12_pex_genes_asso" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Structure of the 12 <italic toggle="yes">PEX</italic> Genes Associated with PBD, ZSS</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                  <th id="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Exons</th>
                  <th id="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Genomic DNA (kb)</th>
                  <th id="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">cDNA (kb)</th>
                  <th id="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein <break/>(# amino acids)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX1</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">24</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">41.5</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3.9</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">1283</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">PXMP3</italic> (<italic toggle="yes">PEX2</italic>)</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">7.4</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.5</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">626</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX3</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">12</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">39</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">373</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX5</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">18.9</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.8</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">602 &#x00026; 639</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX6</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">17</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">15.1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2.4</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">980</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX10</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">7.8</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">326 &#x00026; 345&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX12</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3.8</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">359</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX13</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">31.2</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.2</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">403</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX14</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">9</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">135.5</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1.1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">377</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX16</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8.4</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">346</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX19</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5.7</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0.9</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">299</td>
                </tr>
                <tr>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PEX26</italic>
                  </td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">5</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">10.7</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0.9</td>
                  <td headers="hd_h_pbd.T.structure_of_the_12_pex_genes_asso_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">305</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="pbd.TF.4.1">
                <label>1. </label>
                <p>According to <italic toggle="yes">in silico</italic> analysis, it may be up to 346 amino acids, depending on splicing of the alternate intron 3 acceptor site. It is unclear which is preferred in vivo.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Pathogenic variants.</bold>
<xref ref-type="table" rid="pbd.T.selected_pex1_pathogenic_variants">Table 5</xref> through <xref ref-type="table" rid="pbd.T.selected_pex12_pathogenic_variants">Table 9</xref> summarize the common pathogenic variants (accounting for &#x0003e;90% of affected individuals) in the five <italic toggle="yes">PEX</italic> genes most often associated with PBD, ZSS.</p>
          <sec id="pbd.PEX1">
            <title>
              <italic toggle="yes">PEX1</italic>
            </title>
            <p>Twenty-five variants have been described [<xref ref-type="bibr" rid="pbd.REF.collins.1999.45">Collins &#x00026; Gould 1999</xref>, <xref ref-type="bibr" rid="pbd.REF.walter.2001.35">Walter et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.maxwell.2002.342">Maxwell et al 2002</xref>, <xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>]. The variants p.Gly843Asp and p.Ile700TryfsTer42 represented about 63% of all alleles in 94 individuals with PBD. It has been proposed that the <italic toggle="yes">PEX1</italic> p.Ile700TryfsTer42 and p.Gly843Asp alleles reside on specific haplotypes and arose as founder variants [<xref ref-type="bibr" rid="pbd.REF.collins.1999.45">Collins &#x00026; Gould 1999</xref>], thus suggesting that these sites are not hot spots for recurrent pathogenic variants. Approximately 80% of individuals with a <italic toggle="yes">PEX1</italic> pathogenic variant have at least one of these common alleles.</p>
            <p><xref ref-type="bibr" rid="pbd.REF.maxwell.2002.342">Maxwell et al [2002]</xref> reported an exon 18 frameshift variant (p.Gly973fs) that approached an allele frequency of 10% in their cohort of affected individuals. It is only 3.7% of the total alleles reported by the three main groups, but 21% of alleles were unidentified, so this pathogenic variant may have been missed by other groups if some affected individuals were only screened for the p.Gly843Asp and p.Ile700TryfsTer42 alleles. Otherwise, no other common <italic toggle="yes">PEX1</italic> pathogenic variants have been described.</p>
            <p>Recently, two sequence variants in the <italic toggle="yes">PEX1</italic> promoter region have been identified (c.-137T&#x0003e;C and c.-53C&#x0003e;G) and in vitro reporter assays showed that one increased PEX1 expression, one reduced PEX1 expression, and when present in tandem they cancelled each other out. The authors postulated that these promoter variants could modulate the severity of pathogenic <italic toggle="yes">PEX1</italic> alleles [<xref ref-type="bibr" rid="pbd.REF.maxwell.2005.279">Maxwell et al 2005</xref>].</p>
            <table-wrap id="pbd.T.selected_pex1_pathogenic_variants" orientation="portrait" position="anchor">
              <label>Table 5. </label>
              <caption>
                <p>Selected <italic toggle="yes">PEX1</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;1)</th>
                    <th id="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-137T&#x0003e;C&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/94421467">NM_000466.2</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000457.1">NP_000457.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-53C&#x0003e;G&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2097_2098insT</td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile700TyrfsTer42&#x000a0;<sup>3</sup><break/>(p.Ile700fs)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2528G&#x0003e;A</td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly843Asp&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2916delA</td>
                    <td headers="hd_h_pbd.T.selected_pex1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly973AlafsTer16<break/>(p.Gly973fs)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="pbd.TF.5.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="pbd.TF.5.2">
                  <label>2. </label>
                  <p>Associated with altered gene expression [<xref ref-type="bibr" rid="pbd.REF.maxwell.2005.279">Maxwell et al 2005</xref>]</p>
                </fn>
                <fn id="pbd.TF.5.3">
                  <label>3.&#x000a0;</label>
                  <p>About 80% of individuals with a <italic toggle="yes">PEX1</italic> pathogenic variant have at least one of these two common alleles [<xref ref-type="bibr" rid="pbd.REF.collins.1999.45">Collins &#x00026; Gould 1999</xref>, <xref ref-type="bibr" rid="pbd.REF.walter.2001.35">Walter et al 2001</xref>, <xref ref-type="bibr" rid="pbd.REF.maxwell.2002.342">Maxwell et al 2002</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="pbd.PEX6">
            <title>
              <italic toggle="yes">PEX6</italic>
            </title>
            <p>There are no common pathogenic variants. The largest cohort of affected individuals (N=13) reported were clinically severely affected; 70% of the alleles were frameshift/nonsense and 10% were small in-frame deletions [<xref ref-type="bibr" rid="pbd.REF.zhang.1999.487">Zhang et al 1999</xref>].</p>
            <table-wrap id="pbd.T.selected_pex6_pathogenic_variants" orientation="portrait" position="anchor">
              <label>Table 6. </label>
              <caption>
                <p>Selected <italic toggle="yes">PEX6</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1715C&#x0003e;T</td>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr572Ile</td>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/194018487">NM_000287.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/194018488">NP_000278.3</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2094+2T&#x0003e;C<break/>(IVS10+2T&#x0003e;C)</td>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2426C&#x0003e;T</td>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala809Val</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2534T&#x0003e;C</td>
                    <td headers="hd_h_pbd.T.selected_pex6_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile845Thr</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="pbd.TF.6.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="pbd.PEX26">
            <title>
              <italic toggle="yes">PEX26</italic>
            </title>
            <p>Of the eight individuals studied originally, <italic toggle="yes">PEX26</italic> pathogenic variants were reported for seven. All of the reported variants occurred in exons 2 and 3 [<xref ref-type="bibr" rid="pbd.REF.matsumoto.2003.233">Matsumoto et al 2003</xref>]. Two unrelated individuals with ZS were homozygous for p.Gly89Arg and two unrelated individuals with NALD were homozygous for p.Arg98Trp. Two individuals with IRD were compound heterozygotes for p.[Arg98Trp]+[Leu85fs] and p.[Met1Thr]+[Leu45Pro]. Another individual with ZS was homozygous for p.Leu12ProfsTer103. The fourth individual with ZS had no <italic toggle="yes">PEX26</italic> RNA, but a genomic variant was not reported. Recent studies identified pathogenic variants in five additional individuals, two of whom had one allele in regions beyond exons 2 and 3 [<xref ref-type="bibr" rid="pbd.REF.steinberg.2004.252">Steinberg et al 2004</xref>]. <xref ref-type="bibr" rid="pbd.REF.weller.2005.987">Weller et al [2005]</xref> reported <italic toggle="yes">PEX26</italic> pathogenic variants in ten individuals comprising those originally identified by complementation studies at Kennedy Krieger Institute (<xref ref-type="table" rid="pbd.T.summary_of_molecular_genetic_testi">Table 2</xref>).</p>
            <table-wrap id="pbd.T.selected_pex26_pathogenic_variants" orientation="portrait" position="anchor">
              <label>Table 7. </label>
              <caption>
                <p>Selected <italic toggle="yes">PEX26</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2T&#x0003e;C</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met1Thr</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_3" rowspan="6" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/189083736">NM_001127649.1</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/189083737">NP_001121121.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.34dupC<break/>(Nt35insC)</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu12ProfsTer103</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.134T&#x0003e;C</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu45Pro</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.254dupT</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys86ValfsTer29<break/>(Leu85fs)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.265G&#x0003e;A</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly89Arg</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.292C&#x0003e;T</td>
                    <td headers="hd_h_pbd.T.selected_pex26_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg98Trp</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="pbd.TF.7.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="pbd.PEX10">
            <title>
              <italic toggle="yes">PEX10</italic>
            </title>
            <p>The majority of reported pathogenic variants have been in individuals with ZS, who have frameshift and nonsense variants [<xref ref-type="bibr" rid="pbd.REF.okumoto.1998a.1399">Okumoto et al 1998a</xref>, <xref ref-type="bibr" rid="pbd.REF.warren.1998.347">Warren et al 1998</xref>, <xref ref-type="bibr" rid="pbd.REF.warren.2000.509">Warren et al 2000</xref>]. The pathogenic variant c.814_815delCT is a common allele, especially among the Japanese population, where it appears to have arisen once on an ancestral haplotype [<xref ref-type="bibr" rid="pbd.REF.shimozawa.2003.40">Shimozawa et al 2003</xref>].</p>
            <table-wrap id="pbd.T.selected_pex10_pathogenic_variants" orientation="portrait" position="anchor">
              <label>Table 8. </label>
              <caption>
                <p>Selected <italic toggle="yes">PEX10</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.814_815delCT</td>
                    <td headers="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu271ValfsTer66<break/>(L271fs)</td>
                    <td headers="hd_h_pbd.T.selected_pex10_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/24797087">NM_002617.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/4505715">NP_002608.1</ext-link>
                    </td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="pbd.TF.8.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="pbd.PEX12">
            <title>
              <italic toggle="yes">PEX12</italic>
            </title>
            <p>Of ten individuals reported in the literature, only one had <italic toggle="yes">PEX12</italic> pathogenic missense variants on both alleles [<xref ref-type="bibr" rid="pbd.REF.chang.1997.385">Chang et al 1997</xref>, <xref ref-type="bibr" rid="pbd.REF.chang.1998.1294">Chang &#x00026; Gould 1998</xref>, <xref ref-type="bibr" rid="pbd.REF.okumoto.1998b.4324">Okumoto et al 1998b</xref>]. The majority had nonsense/frameshift/aberrant splicing variants and severe clinical phenotypes. One individual with an IRD phenotype had genomic variants that would be predicted to be severe (frameshift and aberrant splicing), but translation initiation downstream to the initiator ATG yielded a partially functional protein that accounted for the milder IRD phenotype.</p>
            <table-wrap id="pbd.T.selected_pex12_pathogenic_variants" orientation="portrait" position="anchor">
              <label>Table 9. </label>
              <caption>
                <p>Selected <italic toggle="yes">PEX12</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.959C&#x0003e;T</td>
                    <td headers="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser320Phe</td>
                    <td headers="hd_h_pbd.T.selected_pex12_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/196114960">NM_000286.2</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000277.1">NP_000277.1</ext-link>
                    </td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="pbd.References">
        <title>References</title>
        <sec id="pbd.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pbd.Literature_Cited.reflist0">
            <ref id="pbd.REF.agne.2003.635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agne</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meindl</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederhoff</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Einwachter</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehling</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sickmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girzalsky</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunau</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Pex8p: an intraperoxisomal organizer of the peroxisomal import machinery.</article-title>
                <source>Mol Cell</source>
                <volume>11</volume>
                <fpage>635</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">12667447</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.akiyama.2002.1523">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghaedi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A novel pex2 mutant: catalase-deficient but temperature-sensitive PTS1 and PTS2 import.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>293</volume>
                <fpage>1523</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12054689</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.baas.2002.699">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baas</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Laar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorland</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Koning</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Plasma pipecolic acid is frequently elevated in non-peroxisomal disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>25</volume>
                <fpage>699</fpage>
                <lpage>701</lpage>
                <pub-id pub-id-type="pmid">12705501</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.barkovich.1997.1163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barkovich</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peck</surname>
                    <given-names>WW</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>MR of Zellweger syndrome.</article-title>
                <source>AJNR Am J Neuroradiol</source>
                <volume>18</volume>
                <fpage>1163</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">9194444</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.carey.1994.813">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharp</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Pitfalls in the prenatal diagnosis of peroxisomal beta-oxidation defects by chorionic villus sampling.</article-title>
                <source>Prenat Diagn</source>
                <volume>14</volume>
                <fpage>813</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7845889</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.chang.1998.1294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Phenotype-genotype relationships in complementation group 3 of the peroxisome-biogenesis disorders.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>1294</fpage>
                <lpage>306</lpage>
                <pub-id pub-id-type="pmid">9792857</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.chang.1997.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders.</article-title>
                <source>Nat Genet</source>
                <volume>15</volume>
                <fpage>385</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9090384</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.collins.1999.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Identification of a common PEX1 mutation in Zellweger syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>14</volume>
                <fpage>45</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">10447258</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.collins.2000.7516">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalish</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrell</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCaffery</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The peroxisome biogenesis factors pex4p, pex22p, pex1p, and pex6p act in the terminal steps of peroxisomal matrix protein import.</article-title>
                <source>Mol Cell Biol</source>
                <volume>20</volume>
                <fpage>7516</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">11003648</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.corzo.2002.1520">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LePage</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeiss</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyson</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders.</article-title>
                <source>Am J Hum Genet</source>
                <volume>70</volume>
                <fpage>1520</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">11992258</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.depreter.2003.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Depreter</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espeel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Human peroxisomal disorders.</article-title>
                <source>Microsc Res Tech</source>
                <volume>61</volume>
                <fpage>203</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">12740827</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.ghaedi.2000.976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ghaedi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honsho</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>PEX3 is the causal gene responsible for peroxisome membrane assembly-defective Zellweger syndrome of complementation group G.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>976</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">10968777</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.ebberink.2011.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebberink</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koster</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder.</article-title>
                <source>Hum Mutat.</source>
                <volume>32</volume>
                <fpage>59</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">21031596</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.gootjes.2002.1746">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dekker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Biochemical markers predicting survival in peroxisome biogenesis disorders.</article-title>
                <source>Neurology</source>
                <volume>59</volume>
                <fpage>1746</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12473763</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.gootjes.2003.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Resolution of the molecular defect in a patient with peroxisomal mosaicism in the liver.</article-title>
                <source>Adv Exp Med Biol</source>
                <volume>544</volume>
                <fpage>107</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">14713221</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.gootjes.2004.130">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmohl</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dekker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huemer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Von Schutz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Identification of the molecular defect in patients with peroxisomal mosaicism using a novel method involving culturing of cells at 40 degrees C: implications for other inborn errors of metabolism.</article-title>
                <source>Hum Mutat</source>
                <volume>24</volume>
                <fpage>130</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15241794</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.gould.2001">
              <mixed-citation publication-type="book">Gould SJ, Raymond GV, Valle D. The peroxisome biogenesis disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. 8 ed. New York, NY: McGraw-Hill; 2001:3181-218.</mixed-citation>
            </ref>
            <ref id="pbd.REF.gray.1995.486">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schutgens</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>A misdiagnosis of X-linked adrenoleukodystrophy in cultured chorionic villus cells by the measurement of very long chain fatty acids.</article-title>
                <source>Prenat Diagn</source>
                <volume>15</volume>
                <fpage>486</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">7644440</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.imamura.2000.541">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Temperature-sensitive mutation of PEX6 in peroxisome biogenesis disorders in complementation group C (CG-C): comparative study of PEX6 and PEX1.</article-title>
                <source>Pediatr Res</source>
                <volume>48</volume>
                <fpage>541</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11004248</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.imamura.1998.2089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Temperature-sensitive mutation in PEX1 moderates the phenotypes of peroxisome deficiency disorders.</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>2089</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">9817926</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.ito.2001.321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Usuda</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Temperature-sensitive phenotype of Chinese hamster ovary cells defective in PEX5 gene.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>288</volume>
                <fpage>321</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11606046</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.lambert.1989.624">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kriss</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pembrey</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Follow-up and diagnostic reappraisal of 75 patients with Leber's congenital amaurosis.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>107</volume>
                <fpage>624</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">2658617</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.lyons.2004.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lyons</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCormick</surname>
                    <given-names>AQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Leopard spot retinal pigmentation in infancy indicating a peroxisomal disorder.</article-title>
                <source>Br J Ophthalmol</source>
                <volume>88</volume>
                <fpage>191</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">14736770</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.martinez.2001.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Restoring the DHA levels in the brains of Zellweger patients.</article-title>
                <source>J Mol Neurosci.</source>
                <volume>16</volume>
                <fpage>309</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">11478386</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.matsumoto.2003.233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furuki</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyata</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mutations in Novel Peroxin Gene PEX26 That Cause Peroxisome-Biogenesis Disorders of Complementation Group 8 Provide a Genotype-Phenotype Correlation.</article-title>
                <source>Am J Hum Genet</source>
                <volume>73</volume>
                <fpage>233</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">12851857</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.maxwell.2002.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maxwell</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solly</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Svingen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paton</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crane</surname>
                    <given-names>DI</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Novel PEX1 mutations and genotype-phenotype correlations in Australasian peroxisome biogenesis disorder patients.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>342</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">12402331</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.maxwell.2005.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maxwell</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leane</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paton</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crane</surname>
                    <given-names>DI</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel PEX1 coding mutations and 5' UTR regulatory polymorphisms.</article-title>
                <source>Hum Mutat</source>
                <volume>26</volume>
                <fpage>279</fpage>
                <pub-id pub-id-type="pmid">16088892</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.michelakakis.2004.146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Michelakakis</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zafeiriou</surname>
                    <given-names>DI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moraitou</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>PEX1 deficiency presenting as Leber congenital amaurosis.</article-title>
                <source>Pediatr Neurol</source>
                <volume>31</volume>
                <fpage>146</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15301838</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.moser.1995.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naidu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGuinness</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hajra</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups.</article-title>
                <source>J Pediatr</source>
                <volume>127</volume>
                <fpage>13</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">7541833</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.moser.1999.316">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Genotype-phenotype correlations in disorders of peroxisome biogenesis.</article-title>
                <source>Mol Genet Metab</source>
                <volume>68</volume>
                <fpage>316</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">10527683</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.noguer.2010.2277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Noguer</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic Acid ethyl ester.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <volume>51</volume>
                <fpage>2277</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">19933185</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.okumoto.1998a.1399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okumoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1998a</year>
                <article-title>Mutations in PEX10 is the cause of Zellweger peroxisome deficiency syndrome of complementation group B.</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>1399</fpage>
                <lpage>405</lpage>
                <pub-id pub-id-type="pmid">9700193</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.okumoto.1998b.4324">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okumoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1998b</year>
                <article-title>PEX12, the pathogenic gene of group III Zellweger syndrome: cDNA cloning by functional complementation on a CHO cell mutant, patient analysis, and characterization of PEX12p.</article-title>
                <source>Mol Cell Biol</source>
                <volume>18</volume>
                <fpage>4324</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">9632816</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.paker.2010.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Paker</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunness</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brereton</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speedie</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albanna</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dharmaraj</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>GV</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial.</article-title>
                <source>Neurology.</source>
                <volume>75</volume>
                <fpage>826</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">20805528</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.pineda.1999.434">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giros</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espeel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conill</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aracil</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pampols</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Diagnosis and follow-up of a case of peroxisomal disorder with peroxisomal mosaicism.</article-title>
                <source>J Child Neurol</source>
                <volume>14</volume>
                <fpage>434</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10573465</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.plecko.2000.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erwa</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy.</article-title>
                <source>Ann Neurol</source>
                <volume>48</volume>
                <fpage>121</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10894227</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.pollthe.2004.333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Klerk</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenniger-Prick</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Admiraal</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>126A</volume>
                <fpage>333</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15098231</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.raasrothschild.2002.1062">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eshel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espeel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents.</article-title>
                <source>Am J Hum Genet</source>
                <volume>70</volume>
                <fpage>1062</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11873320</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.setchell.1992.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Setchell</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bragetti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmer-Nechemias</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daugherty</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelli</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaccaro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gentili</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Distrutti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dozzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>1992</year>
                <article-title>Oral bile acid treatment and the patient with Zellweger syndrome.</article-title>
                <source>Hepatology</source>
                <volume>15</volume>
                <fpage>198</fpage>
                <lpage>207</lpage>
                <pub-id pub-id-type="pmid">1735522</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.1999a.779">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besley</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1999a</year>
                <article-title>Defective PEX gene products correlate with the protein import, biochemical abnormalities, and phenotypic heterogeneity in peroxisome biogenesis disorders.</article-title>
                <source>J Med Genet</source>
                <volume>36</volume>
                <fpage>779</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">10528859</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.2003.40">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagase</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takemoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Genetic heterogeneity of peroxisome biogenesis disorders among Japanese patients: Evidence for a founder haplotype for the most common PEX10 gene mutation.</article-title>
                <source>Am J Med Genet</source>
                <volume>120A</volume>
                <fpage>40</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12794690</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.1999b.1077">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toyama</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukai</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1999b</year>
                <article-title>Nonsense and temperature-sensitive mutations in PEX13 are the cause of complementation group H of peroxisome biogenesis disorders.</article-title>
                <source>Hum Mol Genet</source>
                <volume>8</volume>
                <fpage>1077</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">10332040</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.2004.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagase</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takemoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koyama</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeannette</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Identification of a new complementation group of the peroxisome biogenesis disorders and PEX14 as the mutated gene.</article-title>
                <source>Hum Mutat.</source>
                <volume>23</volume>
                <fpage>552</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15146459</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.2000.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubourg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Molecular mechanism of detectable catalase-containing particles, peroxisomes, in fibroblasts from a PEX2-defective patient.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>268</volume>
                <fpage>31</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10652207</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.steinberg.2004.252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum.</article-title>
                <source>Mol Genet Metab</source>
                <volume>83</volume>
                <fpage>252</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">15542397</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.steinberg.2005.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katsanis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Biochemical analysis of cultured chorionic villi for the prenatal diagnosis of peroxisomal disorders: biochemical thresholds and molecular sensitivity for maternal cell contamination detection.</article-title>
                <source>J Med Genet</source>
                <volume>42</volume>
                <fpage>38</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">15635073</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.steinberg.1999.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elcioglu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slade</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sankaralingam</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dennis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohammed</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fensom</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Peroxisomal disorders: clinical and biochemical studies in 15 children and prenatal diagnosis in 7 families.</article-title>
                <source>Am J Med Genet</source>
                <volume>85</volume>
                <fpage>502</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">10405451</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.stellaard.1991.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stellaard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schutgens</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>Bile acids in amniotic fluid: promising metabolites for the prenatal diagnosis of peroxisomal disorders.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>14</volume>
                <fpage>353</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">1770790</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.ter_rahe.2004.1022">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>ter Rahe</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majoie</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akkerman</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>den Heeten</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Peroxisomal biogenesis disorder: comparison of conventional MR imaging with diffusion-weighted and diffusion-tensor imaging findings.</article-title>
                <source>Am J Neuroradiol</source>
                <volume>25</volume>
                <fpage>1022</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15205141</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.walter.2001.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gootjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Portsteffen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epplen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunau</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodt</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>35</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">11389485</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.wanders.1995.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dekker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ofman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schutgens</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooijer</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Immunoblot analysis of peroxisomal proteins in liver and fibroblasts from patients.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>18</volume>
                <supplement>Suppl 1</supplement>
                <fpage>101</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9053545</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.warren.1998.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrell</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>347</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">9683594</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.warren.2000.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Phenotype-genotype relationships in PEX10-deficient peroxisome biogenesis disorder patients.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>509</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">10862081</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.waterham.2007.1736">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koster</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Roermund</surname>
                    <given-names>CWT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mooyer</surname>
                    <given-names>PAW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loenard</surname>
                    <given-names>JV</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A lethal; defect of mitochondrial and peroxisomal fission.</article-title>
                <source>N Engl J Med.</source>
                <volume>356</volume>
                <fpage>1736</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17460227</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.watkins.1995.472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGuinness</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hicks</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sisk</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies.</article-title>
                <source>Ann Neurol</source>
                <volume>38</volume>
                <fpage>472</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7668838</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.weller.2005.987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cajigas</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Alternative splicing suggests extended function of PEX26 in peroxisome biogenesis.</article-title>
                <source>Am J Hum Genet</source>
                <volume>76</volume>
                <fpage>987</fpage>
                <lpage>1007</lpage>
                <pub-id pub-id-type="pmid">15858711</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.weller.2000.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preuss</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brosius</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitz</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conzelmann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gartner</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Peroxiosme mosaicism in two PBD patients with mild clinical course and identical PEX1 mutations.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>23</volume>
                <supplement>Suppl 1</supplement>
                <fpage>247</fpage>
                <pub-id pub-id-type="pmid">10863941</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.zhang.1999.487">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paton</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besley</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Genomic structure and identification of 11 novel mutations of the PEX6 (peroxisome assembly factor-2) gene in patients with peroxisome biogenesis disorders.</article-title>
                <source>Hum Mutat</source>
                <volume>13</volume>
                <fpage>487</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">10408779</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="pbd.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="pbd.Suggested_Reading.reflist0">
            <ref id="pbd.REF.mandel.2003.9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Phenotypic variability (heterogeneity) of peroxisomal disorders.</article-title>
                <source>Adv Exp Med Biol</source>
                <volume>544</volume>
                <fpage>9</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">14713208</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.oglesbee.2005.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oglesbee</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>An overview of peroxisomal biogenesis disorders.</article-title>
                <source>Mol Genet Metab</source>
                <volume>84</volume>
                <fpage>299</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">15875330</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.shimozawa.2005.326">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagase</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takemoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular and neurologic findings of peroxisome biogenesis disorders.</article-title>
                <source>J Child Neurol</source>
                <volume>20</volume>
                <fpage>326</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15921234</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.wanders.2004.355">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Metabolic and molecular basis of peroxisomal disorders: a review.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>126A</volume>
                <fpage>355</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">15098234</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.wanders.2005.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders.</article-title>
                <source>Clin Genet</source>
                <volume>67</volume>
                <fpage>107</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">15679822</pub-id>
              </element-citation>
            </ref>
            <ref id="pbd.REF.weller.2003.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Peroxisome biogenesis disorders.</article-title>
                <source>Annu Rev Genomics Hum Genet</source>
                <volume>4</volume>
                <fpage>165</fpage>
                <lpage>211</lpage>
                <pub-id pub-id-type="pmid">14527301</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pbd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pbd.Author_History">
          <title>Author History</title>
          <p>Nancy E Braverman, MS, MD (2003 &#x02013; present)Ann B Moser, BA (2003 &#x02013; present)Hugo W Moser, MD (2003 &#x02013; 2007*)Gerald V Raymond, MD (2003 &#x02013; present)Steven J Steinberg, PhD (2003 &#x02013; present)</p>
          <p>*Hugo W Moser, MD was Professor of Neurology and Pediatrics at Johns Hopkins University School of Medicine and former Director of the Kennedy Krieger Institute in Baltimore. He was a world-renowned expert in the field of neurogenetics. He was best known for his leadership role in understanding, diagnosing, and treating adrenoleukodystrophy (ALD). Dr. Moser died of cancer on January 20, 2007 at age 82. He will be greatly missed by his family, friends, colleagues, and patients.</p>
        </sec>
        <sec id="pbd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>10 May 2012 (cd) Revision: to clarify that prenatal testing using biochemical methods is possible</p>
            </list-item>
            <list-item>
              <p>18 January 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>26 April 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>1 October 2004 (sjs) Revision</p>
            </list-item>
            <list-item>
              <p>12 December 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>1 August 2003 (sjs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
